Samsung Biologics mentioned Wednesday that it’s taking part in BioProcess Worldwide 2024, a worldwide biopharmaceutical convention in Boston, the place it has been showcasing new contract improvement platforms.
BioProcess Worldwide 2024, which started Monday and runs by means of Thursday, is an annual occasion that brings collectively specialists and corporations from world wide to share the most recent developments in biopharmaceutical applied sciences. This yr, over 220 firms are exhibiting.
Samsung Biologics has participated within the convention since 2017, the yr it launched its contract improvement enterprise. On the second day of the occasion, the corporate showcased two new platforms, S-Afucho and S-Opticharge, it mentioned.
S-Afucho is an afucosylated cell line platform designed to supply enhanced antibody-dependent mobile cytotoxicity, or ADCC, antibodies. “Afucosylated” refers back to the elimination of fucose sugars, a modification that enhances ADCC and boosts immune responses. These afucosylated antibodies, Samsung Biologics defined, can be utilized to supply simpler therapeutic antibodies, notably for most cancers remedy. The brand new platform demonstrates 14 occasions better ADCC exercise in comparison with the corporate’s earlier cell traces.
The opposite platform, S-Opticharge, is designed to exactly management cost variants in proteins, a key issue influencing each the efficacy and stability of biopharmaceuticals. By optimizing key course of parameters, together with media choice, components, oxygen ranges and temperature, S-Opticharge permits the manufacturing of high-quality proteins with the precise cost profile required by purchasers, based on Samsung Biologics.
With the addition of S-Afucho and S-Opticharge, Samsung Biologics now presents 9 contract improvement platforms and providers.
On Wednesday, Samsung Biologics hosted a networking seminar for key international purchasers. All through the convention, the corporate is working a sales space to current its long-term imaginative and prescient and product portfolio, which incorporates antibody-drug conjugates and messenger RNA merchandise. Samsung Biologics goals to attain a manufacturing capability of 1.32 million liters by 2032.